Arcus Biosciences (NYSE:RCUS – Free Report) had its price objective lowered by Mizuho from $51.00 to $42.00 in a research note released on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other equities research analysts also recently weighed in on RCUS. Morgan Stanley dropped their price target […]
Arcus Biosciences (NYSE:RCUS) Shares Gap Up to $15 30 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences Increases Stake In Arcus Biosciences To 33% finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy.